Goldman Sachs Group Inc Acrivon Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

  • $780 Billion
  • Q3 2025

A detailed history of Goldman Sachs Group Inc transactions in Acrivon Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 19,742 shares of ACRV stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
19,742
Previous 140,055 85.9%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025
SELL
N/A
-120,313 Reduced 85.9%
19,742 $0
Q2 2025

Aug 14, 2025
BUY
N/A
82,536 Added 143.49%
140,055 $0
Q1 2025

May 09, 2025
SELL
N/A
-180,033 Reduced 75.79%
57,519 $0
Q4 2024

Feb 11, 2025
BUY
N/A
39,384 Added 19.87%
237,552 $0
Q3 2024

Nov 14, 2024
BUY
N/A
173,784 Added 712.7%
198,168 $0
Q2 2024

Aug 13, 2024
BUY
N/A
24,384 New
24,384 $0
Q1 2023

May 14, 2024
SELL
N/A
-25,082 Reduced 64.64%
13,718 $0
Q1 2023

May 11, 2023
SELL
N/A
-25,082 Reduced 64.64%
13,718 $0
Q4 2022

May 14, 2024
BUY
N/A
38,800 New
38,800 $0
Q4 2022

Feb 13, 2023
BUY
N/A
38,800 New
38,800 $0

Others Institutions Holding ACRV

# of Institutions
47
Shares Held
18.2M
Call Options Held
0
Put Options Held
0
View Full List

About Acrivon Therapeutics, Inc.

ACRV Quotes by TradingView
  • Ticker ACRV
More about ACRV
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email